FTC Staffers Greenlight Allergan Divestitures In AbbVie Deal
AbbVie has moved a step closer to antitrust approval of its $63 billion buyout of Allergan, with the companies announcing that Federal Trade Commission staffers had cleared the plan to sell...To view the full article, register now.
Already a subscriber? Click here to view full article